Ekf Diagnostics Regulatory News (EKF)

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Directors' Dealings

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care diagnostics business, announces the following:

Exercise of Options

Following the exercise of options by Paul Foulger, the finance director of the Company, at an exercise price of 20p per share the Company has allotted 625,000 new ordinary shares of 1p each.

Following the exercise of options by Adam Reynolds, a non-executive director of the Company, at an exercise price of 20p per share the Company has allotted 625,000 new ordinary shares of 1p each.

It is expected that admission of the 1,250,000 new ordinary shares to AIM will become effective at 8.00 am on 5 July 2011.

Extension of Option Exercise Period

The Company has also agreed to a 12 month extension of the exercise period relating to options previously granted to Gordon Hall, non-executive director of the Company, over 500,000 new ordinary shares. The latest date for exercise of these options has now been extended by 12 months to 28 June 2012. The exercise price remains at 20p per share.

Total Voting Rights

Following admission of the new ordinary shares, the Company will have a single class of shares being ordinary shares of 1 pence each ("Ordinary Shares") and there will be 251,228,134 Ordinary Shares in issue, each carrying one vote per Ordinary Share. The Company does not hold any Ordinary Shares in treasury. The total number of voting rights in the Company's Ordinary Shares will be 251,228,134 and this number may be used by shareholders as the denominator in calculations to determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Services Authority's Disclosure and Transparency Rules.

Enquiries: